Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population
Objective This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population. Methods We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun l...
Gespeichert in:
| Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2023-04, Vol.75 (4), p.620-629 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 629 |
|---|---|
| container_issue | 4 |
| container_start_page | 620 |
| container_title | Arthritis & rheumatology (Hoboken, N.J.) |
| container_volume | 75 |
| creator | Mecoli, Christopher A. Igusa, Tak Chen, Mengkun Wang, XingYao Albayda, Jemima Paik, Julie J. Tiniakou, Eleni Adler, Brittany Richardson, Carrie Kelly, Will Danoff, Sonye Mammen, Andrew L. Platz, Elizabeth A. Rosen, Antony Christopher‐Stine, Lisa Casciola‐Rosen, Livia Shah, Ami A. |
| description | Objective
This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population.
Methods
We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun line blot, enzyme‐linked immunosorbent assay, and immunoprecipitation. We calculated standardized prevalence ratios (SPRs) and adjusted for calendar year, age, sex, race, and ethnicity by comparing observed cancers in IIM patients versus expected cancers in the general population using the Surveillance, Epidemiology, and End Results registry.
Results
Of 1,172 IIM patients, 203 (17%) patients with a cancer history were studied. Over a median follow‐up of 5.2 years, the observed number of IIM patients diagnosed with cancer was increased 1.43‐fold (SPR 1.43 [95% confidence interval (95% CI) 1.15–1.77]; P = 0.002). Within 3 years of IIM symptom onset, an increased SPR was observed for anti–transcription intermediary factor 1γ (anti‐TIF1γ)–positive patients for ovarian and breast cancer (ovarian SPR 18.39 [95% CI 5.01–47.08], P |
| doi_str_mv | 10.1002/art.42311 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9873833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2792484761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4081-ab27bb89c02ca69a06a15fb26a06ef915b72fc1e694cef5abc1e0104e0d6db773</originalsourceid><addsrcrecordid>eNp1kUFLHTEUhYO0qFgX_QMl0E1dPE0ymcxkU5CHtQ8sFbXrkMnc9EVmkmmSsbx_39hRaQvN5h64HyfnchB6S8kpJYSd6ZhPOaso3UOHrGJiVTNSv3rWVNIDdJzSPSlPNkSQeh8dVHXbtIS2hyjezl2CnHCweNO7MOm8dQZvvB30OOoc4g5_2YXkskv4wkdnttBjGyJeB59hnELUHsKc8Fp7AxHfwKCzewCcA85bwJfgIeoBX4dpftwE_wa9tnpIcPw0j9C3Txd368-rq6-Xm_X51cpw0tKV7ljTda00hBktpCZC09p2TBQFVtK6a5g1FITkBmytu6IJJRxIL_quaaoj9HHxneZuhN6AzyWImqIbddypoJ36e-PdVn0PD0q2TdVWVTH48GQQw48ZUlajSwaGYblYsfK1FJxyXtD3_6D3YY6-nKdYIxlveSNooU4WysSQUgT7EoYS9VimKmWq32UW9t2f6V_I5-oKcLYAP90Au_87qfObu8XyF3U9q38</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2792484761</pqid></control><display><type>article</type><title>Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Mecoli, Christopher A. ; Igusa, Tak ; Chen, Mengkun ; Wang, XingYao ; Albayda, Jemima ; Paik, Julie J. ; Tiniakou, Eleni ; Adler, Brittany ; Richardson, Carrie ; Kelly, Will ; Danoff, Sonye ; Mammen, Andrew L. ; Platz, Elizabeth A. ; Rosen, Antony ; Christopher‐Stine, Lisa ; Casciola‐Rosen, Livia ; Shah, Ami A.</creator><creatorcontrib>Mecoli, Christopher A. ; Igusa, Tak ; Chen, Mengkun ; Wang, XingYao ; Albayda, Jemima ; Paik, Julie J. ; Tiniakou, Eleni ; Adler, Brittany ; Richardson, Carrie ; Kelly, Will ; Danoff, Sonye ; Mammen, Andrew L. ; Platz, Elizabeth A. ; Rosen, Antony ; Christopher‐Stine, Lisa ; Casciola‐Rosen, Livia ; Shah, Ami A.</creatorcontrib><description>Objective
This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population.
Methods
We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun line blot, enzyme‐linked immunosorbent assay, and immunoprecipitation. We calculated standardized prevalence ratios (SPRs) and adjusted for calendar year, age, sex, race, and ethnicity by comparing observed cancers in IIM patients versus expected cancers in the general population using the Surveillance, Epidemiology, and End Results registry.
Results
Of 1,172 IIM patients, 203 (17%) patients with a cancer history were studied. Over a median follow‐up of 5.2 years, the observed number of IIM patients diagnosed with cancer was increased 1.43‐fold (SPR 1.43 [95% confidence interval (95% CI) 1.15–1.77]; P = 0.002). Within 3 years of IIM symptom onset, an increased SPR was observed for anti–transcription intermediary factor 1γ (anti‐TIF1γ)–positive patients for ovarian and breast cancer (ovarian SPR 18.39 [95% CI 5.01–47.08], P < 0.001; breast SPR 3.84 [95% CI 1.99–6.71], P < 0.001). As expected, anti‐TIF1γ positivity was associated with a significantly elevated SPR; however, only 55% (36 of 66) of all cancers within 3 years of dermatomyositis onset were observed in anti‐TIF1γ–positive patients. Other myositis‐specific autoantibodies, including anti–Mi‐2, anti–small ubiquitin‐like modifier activating enzyme (SAE), and anti‐nuclear matrix protein 2 (NXP‐2), accounted for 26% (17 of 66) of cancers diagnosed within 3 years of dermatomyositis onset. No cancer association, positive or negative, was observed for patients with antisynthetase, anti–melanoma differentiation–associated protein 5 (anti–MDA‐5), or anti–hydroxymethylglutaryl‐coenzyme A reductase (anti‐HMGCR) antibodies.
Conclusion
In a tertiary referral center population, anti‐TIF1γ was most strongly associated with breast and ovarian cancer. Patients with antisynthetase, anti–MDA‐5, or anti‐HMGCR antibodies had the same cancer risk as the general population.</description><identifier>ISSN: 2326-5191</identifier><identifier>ISSN: 2326-5205</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.42311</identifier><identifier>PMID: 35878018</identifier><language>eng</language><publisher>Boston, USA: Wiley Periodicals, Inc</publisher><subject>Antibodies ; Autoantibodies ; Breast cancer ; Coenzyme A ; Dermatomyositis ; Dermatomyositis - epidemiology ; Enzymes ; Epidemiology ; Health risks ; Humans ; Hydroxymethylglutaryl-CoA reductase ; Immunoprecipitation ; Inflammation ; Inflammatory diseases ; Malignancy ; Matrix protein ; Melanoma ; Minority & ethnic groups ; Musculoskeletal diseases ; Myopathy ; Myositis ; Neoplasms - epidemiology ; Ovarian cancer ; Population studies ; Proteins ; Reductases ; Retrospective Studies ; Ubiquitin</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2023-04, Vol.75 (4), p.620-629</ispartof><rights>2022 American College of Rheumatology</rights><rights>2022 American College of Rheumatology.</rights><rights>2023 American College of Rheumatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4081-ab27bb89c02ca69a06a15fb26a06ef915b72fc1e694cef5abc1e0104e0d6db773</citedby><cites>FETCH-LOGICAL-c4081-ab27bb89c02ca69a06a15fb26a06ef915b72fc1e694cef5abc1e0104e0d6db773</cites><orcidid>0000-0001-8436-1601 ; 0000-0003-4749-870X ; 0000-0003-3732-3252 ; 0000-0002-8030-9504 ; 0000-0002-7150-7306 ; 0000-0002-4172-1539 ; 0000-0002-1429-8392</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.42311$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.42311$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35878018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mecoli, Christopher A.</creatorcontrib><creatorcontrib>Igusa, Tak</creatorcontrib><creatorcontrib>Chen, Mengkun</creatorcontrib><creatorcontrib>Wang, XingYao</creatorcontrib><creatorcontrib>Albayda, Jemima</creatorcontrib><creatorcontrib>Paik, Julie J.</creatorcontrib><creatorcontrib>Tiniakou, Eleni</creatorcontrib><creatorcontrib>Adler, Brittany</creatorcontrib><creatorcontrib>Richardson, Carrie</creatorcontrib><creatorcontrib>Kelly, Will</creatorcontrib><creatorcontrib>Danoff, Sonye</creatorcontrib><creatorcontrib>Mammen, Andrew L.</creatorcontrib><creatorcontrib>Platz, Elizabeth A.</creatorcontrib><creatorcontrib>Rosen, Antony</creatorcontrib><creatorcontrib>Christopher‐Stine, Lisa</creatorcontrib><creatorcontrib>Casciola‐Rosen, Livia</creatorcontrib><creatorcontrib>Shah, Ami A.</creatorcontrib><title>Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population.
Methods
We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun line blot, enzyme‐linked immunosorbent assay, and immunoprecipitation. We calculated standardized prevalence ratios (SPRs) and adjusted for calendar year, age, sex, race, and ethnicity by comparing observed cancers in IIM patients versus expected cancers in the general population using the Surveillance, Epidemiology, and End Results registry.
Results
Of 1,172 IIM patients, 203 (17%) patients with a cancer history were studied. Over a median follow‐up of 5.2 years, the observed number of IIM patients diagnosed with cancer was increased 1.43‐fold (SPR 1.43 [95% confidence interval (95% CI) 1.15–1.77]; P = 0.002). Within 3 years of IIM symptom onset, an increased SPR was observed for anti–transcription intermediary factor 1γ (anti‐TIF1γ)–positive patients for ovarian and breast cancer (ovarian SPR 18.39 [95% CI 5.01–47.08], P < 0.001; breast SPR 3.84 [95% CI 1.99–6.71], P < 0.001). As expected, anti‐TIF1γ positivity was associated with a significantly elevated SPR; however, only 55% (36 of 66) of all cancers within 3 years of dermatomyositis onset were observed in anti‐TIF1γ–positive patients. Other myositis‐specific autoantibodies, including anti–Mi‐2, anti–small ubiquitin‐like modifier activating enzyme (SAE), and anti‐nuclear matrix protein 2 (NXP‐2), accounted for 26% (17 of 66) of cancers diagnosed within 3 years of dermatomyositis onset. No cancer association, positive or negative, was observed for patients with antisynthetase, anti–melanoma differentiation–associated protein 5 (anti–MDA‐5), or anti–hydroxymethylglutaryl‐coenzyme A reductase (anti‐HMGCR) antibodies.
Conclusion
In a tertiary referral center population, anti‐TIF1γ was most strongly associated with breast and ovarian cancer. Patients with antisynthetase, anti–MDA‐5, or anti‐HMGCR antibodies had the same cancer risk as the general population.</description><subject>Antibodies</subject><subject>Autoantibodies</subject><subject>Breast cancer</subject><subject>Coenzyme A</subject><subject>Dermatomyositis</subject><subject>Dermatomyositis - epidemiology</subject><subject>Enzymes</subject><subject>Epidemiology</subject><subject>Health risks</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA reductase</subject><subject>Immunoprecipitation</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Malignancy</subject><subject>Matrix protein</subject><subject>Melanoma</subject><subject>Minority & ethnic groups</subject><subject>Musculoskeletal diseases</subject><subject>Myopathy</subject><subject>Myositis</subject><subject>Neoplasms - epidemiology</subject><subject>Ovarian cancer</subject><subject>Population studies</subject><subject>Proteins</subject><subject>Reductases</subject><subject>Retrospective Studies</subject><subject>Ubiquitin</subject><issn>2326-5191</issn><issn>2326-5205</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFLHTEUhYO0qFgX_QMl0E1dPE0ymcxkU5CHtQ8sFbXrkMnc9EVmkmmSsbx_39hRaQvN5h64HyfnchB6S8kpJYSd6ZhPOaso3UOHrGJiVTNSv3rWVNIDdJzSPSlPNkSQeh8dVHXbtIS2hyjezl2CnHCweNO7MOm8dQZvvB30OOoc4g5_2YXkskv4wkdnttBjGyJeB59hnELUHsKc8Fp7AxHfwKCzewCcA85bwJfgIeoBX4dpftwE_wa9tnpIcPw0j9C3Txd368-rq6-Xm_X51cpw0tKV7ljTda00hBktpCZC09p2TBQFVtK6a5g1FITkBmytu6IJJRxIL_quaaoj9HHxneZuhN6AzyWImqIbddypoJ36e-PdVn0PD0q2TdVWVTH48GQQw48ZUlajSwaGYblYsfK1FJxyXtD3_6D3YY6-nKdYIxlveSNooU4WysSQUgT7EoYS9VimKmWq32UW9t2f6V_I5-oKcLYAP90Au_87qfObu8XyF3U9q38</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Mecoli, Christopher A.</creator><creator>Igusa, Tak</creator><creator>Chen, Mengkun</creator><creator>Wang, XingYao</creator><creator>Albayda, Jemima</creator><creator>Paik, Julie J.</creator><creator>Tiniakou, Eleni</creator><creator>Adler, Brittany</creator><creator>Richardson, Carrie</creator><creator>Kelly, Will</creator><creator>Danoff, Sonye</creator><creator>Mammen, Andrew L.</creator><creator>Platz, Elizabeth A.</creator><creator>Rosen, Antony</creator><creator>Christopher‐Stine, Lisa</creator><creator>Casciola‐Rosen, Livia</creator><creator>Shah, Ami A.</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8436-1601</orcidid><orcidid>https://orcid.org/0000-0003-4749-870X</orcidid><orcidid>https://orcid.org/0000-0003-3732-3252</orcidid><orcidid>https://orcid.org/0000-0002-8030-9504</orcidid><orcidid>https://orcid.org/0000-0002-7150-7306</orcidid><orcidid>https://orcid.org/0000-0002-4172-1539</orcidid><orcidid>https://orcid.org/0000-0002-1429-8392</orcidid></search><sort><creationdate>202304</creationdate><title>Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population</title><author>Mecoli, Christopher A. ; Igusa, Tak ; Chen, Mengkun ; Wang, XingYao ; Albayda, Jemima ; Paik, Julie J. ; Tiniakou, Eleni ; Adler, Brittany ; Richardson, Carrie ; Kelly, Will ; Danoff, Sonye ; Mammen, Andrew L. ; Platz, Elizabeth A. ; Rosen, Antony ; Christopher‐Stine, Lisa ; Casciola‐Rosen, Livia ; Shah, Ami A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4081-ab27bb89c02ca69a06a15fb26a06ef915b72fc1e694cef5abc1e0104e0d6db773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Autoantibodies</topic><topic>Breast cancer</topic><topic>Coenzyme A</topic><topic>Dermatomyositis</topic><topic>Dermatomyositis - epidemiology</topic><topic>Enzymes</topic><topic>Epidemiology</topic><topic>Health risks</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA reductase</topic><topic>Immunoprecipitation</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Malignancy</topic><topic>Matrix protein</topic><topic>Melanoma</topic><topic>Minority & ethnic groups</topic><topic>Musculoskeletal diseases</topic><topic>Myopathy</topic><topic>Myositis</topic><topic>Neoplasms - epidemiology</topic><topic>Ovarian cancer</topic><topic>Population studies</topic><topic>Proteins</topic><topic>Reductases</topic><topic>Retrospective Studies</topic><topic>Ubiquitin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mecoli, Christopher A.</creatorcontrib><creatorcontrib>Igusa, Tak</creatorcontrib><creatorcontrib>Chen, Mengkun</creatorcontrib><creatorcontrib>Wang, XingYao</creatorcontrib><creatorcontrib>Albayda, Jemima</creatorcontrib><creatorcontrib>Paik, Julie J.</creatorcontrib><creatorcontrib>Tiniakou, Eleni</creatorcontrib><creatorcontrib>Adler, Brittany</creatorcontrib><creatorcontrib>Richardson, Carrie</creatorcontrib><creatorcontrib>Kelly, Will</creatorcontrib><creatorcontrib>Danoff, Sonye</creatorcontrib><creatorcontrib>Mammen, Andrew L.</creatorcontrib><creatorcontrib>Platz, Elizabeth A.</creatorcontrib><creatorcontrib>Rosen, Antony</creatorcontrib><creatorcontrib>Christopher‐Stine, Lisa</creatorcontrib><creatorcontrib>Casciola‐Rosen, Livia</creatorcontrib><creatorcontrib>Shah, Ami A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mecoli, Christopher A.</au><au>Igusa, Tak</au><au>Chen, Mengkun</au><au>Wang, XingYao</au><au>Albayda, Jemima</au><au>Paik, Julie J.</au><au>Tiniakou, Eleni</au><au>Adler, Brittany</au><au>Richardson, Carrie</au><au>Kelly, Will</au><au>Danoff, Sonye</au><au>Mammen, Andrew L.</au><au>Platz, Elizabeth A.</au><au>Rosen, Antony</au><au>Christopher‐Stine, Lisa</au><au>Casciola‐Rosen, Livia</au><au>Shah, Ami A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2023-04</date><risdate>2023</risdate><volume>75</volume><issue>4</issue><spage>620</spage><epage>629</epage><pages>620-629</pages><issn>2326-5191</issn><issn>2326-5205</issn><eissn>2326-5205</eissn><abstract>Objective
This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population.
Methods
We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun line blot, enzyme‐linked immunosorbent assay, and immunoprecipitation. We calculated standardized prevalence ratios (SPRs) and adjusted for calendar year, age, sex, race, and ethnicity by comparing observed cancers in IIM patients versus expected cancers in the general population using the Surveillance, Epidemiology, and End Results registry.
Results
Of 1,172 IIM patients, 203 (17%) patients with a cancer history were studied. Over a median follow‐up of 5.2 years, the observed number of IIM patients diagnosed with cancer was increased 1.43‐fold (SPR 1.43 [95% confidence interval (95% CI) 1.15–1.77]; P = 0.002). Within 3 years of IIM symptom onset, an increased SPR was observed for anti–transcription intermediary factor 1γ (anti‐TIF1γ)–positive patients for ovarian and breast cancer (ovarian SPR 18.39 [95% CI 5.01–47.08], P < 0.001; breast SPR 3.84 [95% CI 1.99–6.71], P < 0.001). As expected, anti‐TIF1γ positivity was associated with a significantly elevated SPR; however, only 55% (36 of 66) of all cancers within 3 years of dermatomyositis onset were observed in anti‐TIF1γ–positive patients. Other myositis‐specific autoantibodies, including anti–Mi‐2, anti–small ubiquitin‐like modifier activating enzyme (SAE), and anti‐nuclear matrix protein 2 (NXP‐2), accounted for 26% (17 of 66) of cancers diagnosed within 3 years of dermatomyositis onset. No cancer association, positive or negative, was observed for patients with antisynthetase, anti–melanoma differentiation–associated protein 5 (anti–MDA‐5), or anti–hydroxymethylglutaryl‐coenzyme A reductase (anti‐HMGCR) antibodies.
Conclusion
In a tertiary referral center population, anti‐TIF1γ was most strongly associated with breast and ovarian cancer. Patients with antisynthetase, anti–MDA‐5, or anti‐HMGCR antibodies had the same cancer risk as the general population.</abstract><cop>Boston, USA</cop><pub>Wiley Periodicals, Inc</pub><pmid>35878018</pmid><doi>10.1002/art.42311</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8436-1601</orcidid><orcidid>https://orcid.org/0000-0003-4749-870X</orcidid><orcidid>https://orcid.org/0000-0003-3732-3252</orcidid><orcidid>https://orcid.org/0000-0002-8030-9504</orcidid><orcidid>https://orcid.org/0000-0002-7150-7306</orcidid><orcidid>https://orcid.org/0000-0002-4172-1539</orcidid><orcidid>https://orcid.org/0000-0002-1429-8392</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2326-5191 |
| ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2023-04, Vol.75 (4), p.620-629 |
| issn | 2326-5191 2326-5205 2326-5205 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9873833 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Antibodies Autoantibodies Breast cancer Coenzyme A Dermatomyositis Dermatomyositis - epidemiology Enzymes Epidemiology Health risks Humans Hydroxymethylglutaryl-CoA reductase Immunoprecipitation Inflammation Inflammatory diseases Malignancy Matrix protein Melanoma Minority & ethnic groups Musculoskeletal diseases Myopathy Myositis Neoplasms - epidemiology Ovarian cancer Population studies Proteins Reductases Retrospective Studies Ubiquitin |
| title | Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T14%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subsets%20of%20Idiopathic%20Inflammatory%20Myositis%20Enriched%20for%20Contemporaneous%20Cancer%20Relative%20to%20the%20General%20Population&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Mecoli,%20Christopher%20A.&rft.date=2023-04&rft.volume=75&rft.issue=4&rft.spage=620&rft.epage=629&rft.pages=620-629&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.42311&rft_dat=%3Cproquest_pubme%3E2792484761%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2792484761&rft_id=info:pmid/35878018&rfr_iscdi=true |